首页> 外文期刊>JMM Case Reports >Multi-drug-resistant Enterococcus faecium bacteraemia in a liver transplant recipient
【24h】

Multi-drug-resistant Enterococcus faecium bacteraemia in a liver transplant recipient

机译:肝脏移植受体中的多药肠球菌粪便菌血症

获取原文
       

摘要

Introduction. Enterococcus faecium is a commensal organism commonly colonizing the human gastrointestinal tract. Although it is generally a non-virulent organism, E. faecium can cause significant morbidity and mortality due to its inherent and acquired resistances to commonly used antimicrobials. Patients who are immunosuppressed are particularly vulnerable. Case presentation. A 65–75-year-old patient with a history of an orthotopic liver transplant for hepatitis C infection and diabetes was re-admitted to the hospital with abdominal pain and fever. The patient had several recent admissions related to the presentation reported here, which included treatment with a prolonged course of broad-spectrum antibiotics. The patient was found to have a recurrent liver abscess and blood cultures grew vancomycin-resistant E. faecium, non-susceptible to all tested agents: ampicillin, penicillin, vancomycin, daptomycin and linezolid. The patient was started initially on chloramphenicol intravenously while awaiting additional susceptibility testing, which ultimately revealed chloramphenicol non-susceptibility. Tigecycline was started but the patient ultimately decided to pursue hospice care. Conclusion. Multi-drug-resistant organisms are increasingly being recognized and are associated with poorer outcomes, particularly in immunosuppressed patients. We describe a particularly resistant organism and discuss potential therapeutic options.
机译:介绍。肠球菌粪便是一种共生的人类,通常殖民化人胃肠道。虽然它通常是非毒性生物体,但由于其固有和获得的抗菌药物的固有和获得的电阻,E.粪便可能导致显着的发病率和死亡率。免疫抑制的患者特别容易受到伤害。案例演示。一个65-75岁的患者,具有患有丙型肝炎感染和糖尿病的原位肝脏移植的历史,患有腹痛和发烧的医院被重新入围。该患者有几个与此处报告的介绍相关的录取,其中包括延长型广谱抗生素的治疗。发现患者具有复发性肝脏脓肿和血液培养,抗万古霉素抗性E.粪便,对所有测试剂的不敏感:氨苄青霉素,青霉素,万古霉素,达摩霉素和线唑胺。最初在等待额外的易感测试的同时最初在氯霉素上启动患者,这最终揭示了氯霉素的不敏感性。 Tigecycline开始,但患者最终决定追求临终关怀。结论。越来越多地被认识到多种耐药生物,并且与较差的结果有关,特别是在免疫抑制患者中。我们描述了一种特别抗性的生物体,并讨论潜在的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号